Table 1

Demographics, clinical features, responsible pathogens, and outcomes of patients treated with aerosolized colistin
Characteristic
 Patient


1
 2
 3
 4
 5
 6
 7
 8
Medical history
 Fatty liver, arterial hypertension
 Smoking, arterial hypertension, pulmonary oedema, heart attack, mild chronic renal failure
 Liver hamartoma, chronic obstructive pulmonary disease, urinary incontinence, hypothyroidism, Sjögren's syndrome, excised left frontal lobe meningioma
 Catarract, cholosteatoma, arterial hypertension, urinary tract infection 3 weeks before admission
 Wolff–Parkinson–White syndrome, chronic renal failure (polycystic kidney disease), ankylosing spondylitis
 Smoking, obesity, chronic obstructive pulmonary disease
 Arterial hypertension, chronic renal dysfunction (creatinine clearance 75–80 ml/min), adenoma of hypophysis, epileptic seizures, cerebral haemorrhage
 Arterial hypertension, cerebral arteriovenous malformation
Reason for admission
 Stomach lymphoma
 Acute myocardial infarction
 Epileptic seizures
 Fever, headache
 Multitrauma patient, C4–C5 fractures due to car accident, functional dissection of spinal cord, haemothorax
 Oesophageal perforation
 Adenoma of hypophysis, cerebral haemorrhage
 Pneumonia, sleep apnoea syndrome, cerebral haemorrhage
Discharge diagnosis
 Stomach lymphoma, nosocomial pneumonia
 Acute myocardial infarction, nosocomial pneumonia
 Postsurgical intracranial haematoma, pulmonary embolism, inferior vena cava filter placement
 Pneumococcal meningitis, hydrocephalus, pulmonary embolism, pneumonia, urinary tract infection
 Septic shock, multiple organ failure
 Mediastinitis
 Pneumonia
 Pneumonia, sleep apnoea syndrome, cerebral haemorrhage
APACHE II score on ICU admission
 14
 17
 17
 9
 12
 17
 19
 12
APACHE II score on first day of colistin treatment
 10
 29
 19
 8
 19
 20
 18
 14
Surgery during hospitalization
 Liver biopsy, partial gastrectomy
 Coronary artery bypass surgery
 Drainage of postsurgical haematoma of left frontal lobe, inferior vena cava filter placement
 Endoscopic ethmoidectomy, surgical drainage of the frontal and maxillary sinuses
 Spinal arthrodesis surgery (C5–T1)
 Surgical repair of oesophageal perforation
 Excision of pituitary adenoma
 Embolization of arteriovenous malformation
Duration of mechanical ventilation (days)
 10
 16
 5
 18
 65
 25
 8
 8
Time from ICU admission to develop the infection for which aerosolized colistin was given (days)
 8
 1
 7
 22
 24
 1
 7
 5
Site of infection
 Pneumonia (VAP)
 Pneumonia, urinary tract infection
 Bacteraemia, pneumonia (VAP)
 Pneumonia (VAP)
 Pneumonia (VAP)
 Pneumonia
 Pneumonia (VAP)
 Pneumonia (VAP)
Isolated micro-organism (source)
 Acinetobacter baumannii (BAL)
 A baumannii (bronchial secretions)
 A baumannii (blood), A baumannii (bronchial secretions)
 Pseudomonas aeruginosa (bronchial secretions)
 A baumannii (bronchial secretions)
 A baumannii (BAL)
 A baumannii (bronchial secretions)
 A baumannii (bronchial secretions)
Susceptibility of the isolated pathogen
 MDR (sensitive to colistin and gentamycin)
 COS
 COS
 COS
 MDR (sensitive to colistin and gentamycin)
 COS
 MDR (sensitive to colistin and gentamycin)
 MDR (sensitive to colistin and gentamycin)
Duration/dosage of nebulized colistin
 6 days/1 million IU q8 h
 13 days/1 million IU q8 h
 10 days/0.5 million IU q8 h
 5 days/1.5 million IU q8 h
 7 days/2 million IU q8 h
 3 days/1 million IU q8 h
 8 days/0.5 million IU q6 h
 19 days/1 million IU q8 h
Duration/dosage of concomitant intravenous antibiotic treatment
 Colistin: 2 days/3 million IU q8 h, 6 days/2 million IU q8 h
Levofloxacin: 3 days/500 mg q24 h
Co-trimoxazole: 4 days/3 ampules q8 h
Ciprofloxacin 4 days/400 mg q12 h
 Colistin: 14 days/1 million IU q8 h
Meropenem: 12 days/1 g q12 h
 Colistin: 26 days/3 million IU q8 h
Meropenem: 26 days/2 g q8 h
 She received intravenous colistin before nebulized treatment (7 days/1 million IU q8 h) and after the end of nebulized treatment (32 days/1 million IU q8 h)
 Tobramycin: 7 days/80 mg q24 h
Aztreonam: 3 days/1 g q8 h
 Colistin: 14 days/2 million IU q8 h
Meropenem: 15 days/2 g q8 h
Gentamicin: 8 days/80 mg q8 h
 Colistin: 8 days/2 million IU q8 h
Meropenem: 4 days/2 g q8 h
 Meropenem: 27 days/2 g q8 h
Gentamicin: 27 days/80 mg q8 h
Duration of hospitalization (days)
 17
 16
 41
 234
 94
 25
 36
 40
Duration of ICU stay (days)
 11
 16
 21
 62
 95
 25
 13
 20
Outcome of infection
 Cure
 Improvement
 Cure
 Improvement
 Deterioration
 Improvement
 Cure
 Cure
Outcome of patient
 Discharge
 Discharge
 Discharge
 Discharge
 Death
 Discharge
 Discharge
 Discharge
Serum creatinine value (mg/dl) on the first day of aerosolized colistin administration
 1.1
 5.2
 1
 0.4
 2.4
 0.6
 0.8
 0.8
Serum creatinine value (mg/dl) at the end of aerosolized colistin administration
 0.8
 4.5
 0.9
 0.5
 3.8
 0.5
 0.7
 0,6

APACHE, Acute Physiology and Chronic Health Evaluation; BAL, bronchoalveolar lavage; COS, colistin-only-sensitive; ICU, intensive care unit; MDR, multidrug-resistant; VAP, ventilator-associated pneumonia.

Michalopoulos et al. Critical Care 2005 9:R53   doi:10.1186/cc3020